CN101513526B - 联合疫苗在肿瘤治疗中的应用 - Google Patents
联合疫苗在肿瘤治疗中的应用 Download PDFInfo
- Publication number
- CN101513526B CN101513526B CN2008102199620A CN200810219962A CN101513526B CN 101513526 B CN101513526 B CN 101513526B CN 2008102199620 A CN2008102199620 A CN 2008102199620A CN 200810219962 A CN200810219962 A CN 200810219962A CN 101513526 B CN101513526 B CN 101513526B
- Authority
- CN
- China
- Prior art keywords
- vaccine
- purposes
- combined vaccine
- tumor
- combined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 88
- 206010028980 Neoplasm Diseases 0.000 title abstract description 39
- 229940041323 measles vaccine Drugs 0.000 claims abstract description 7
- 229940021648 varicella vaccine Drugs 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 23
- 239000002502 liposome Substances 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 239000003463 adsorbent Substances 0.000 claims description 4
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 claims description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 2
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 229940073490 sodium glutamate Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 32
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 10
- 230000007547 defect Effects 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 206010003445 Ascites Diseases 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 238000010254 subcutaneous injection Methods 0.000 description 9
- 239000007929 subcutaneous injection Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 230000002238 attenuated effect Effects 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 201000005505 Measles Diseases 0.000 description 5
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 5
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003961 penetration enhancing agent Substances 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 201000005702 Pertussis Diseases 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 201000005404 rubella Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229960005097 diphtheria vaccines Drugs 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 208000005252 hepatitis A Diseases 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical group CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 229940066827 pertussis vaccine Drugs 0.000 description 3
- 229960003131 rubella vaccine Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010034038 Parotitis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 229940025250 camphora Drugs 0.000 description 2
- 239000010238 camphora Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229940095293 mumps vaccine Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 229960002766 tetanus vaccines Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
- 229940124847 Diphtheria-Tetanus vaccine Drugs 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229940124843 Measles-Mumps vaccine Drugs 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- YHQUYMYYBCNHGN-UHFFFAOYSA-N S=[Hg]=S Chemical compound S=[Hg]=S YHQUYMYYBCNHGN-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940124832 acellular pertussis vaccine Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960001201 live attenuated varicella Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102199620A CN101513526B (zh) | 2008-12-15 | 2008-12-15 | 联合疫苗在肿瘤治疗中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102199620A CN101513526B (zh) | 2008-12-15 | 2008-12-15 | 联合疫苗在肿瘤治疗中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101513526A CN101513526A (zh) | 2009-08-26 |
CN101513526B true CN101513526B (zh) | 2012-12-26 |
Family
ID=41038248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008102199620A Active CN101513526B (zh) | 2008-12-15 | 2008-12-15 | 联合疫苗在肿瘤治疗中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101513526B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101669973B (zh) * | 2008-09-12 | 2013-06-19 | 马逸冰 | 一种治疗癌症的生物免疫增强剂组合物 |
CN104042628B (zh) * | 2013-03-15 | 2017-04-12 | 复旦大学 | 氢氧化铝在制备治疗肝癌药物中的应用 |
CN104341499B (zh) * | 2014-11-06 | 2017-05-24 | 遵义医学院 | 抗麻疹与百白破四价卵黄抗体制剂的制备工艺 |
CN105999260B (zh) * | 2016-05-13 | 2019-12-10 | 四川大学 | 氢氧化铝凝胶-氯化钠复合免疫佐剂及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1460521A (zh) * | 2003-06-06 | 2003-12-10 | 长春生物制品研究所 | 重组乙型肝炎卡介苗联合疫苗及制备方法 |
CN1602956A (zh) * | 2004-07-27 | 2005-04-06 | 张锦铭 | 治病用灭活卡介苗 |
-
2008
- 2008-12-15 CN CN2008102199620A patent/CN101513526B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1460521A (zh) * | 2003-06-06 | 2003-12-10 | 长春生物制品研究所 | 重组乙型肝炎卡介苗联合疫苗及制备方法 |
CN1602956A (zh) * | 2004-07-27 | 2005-04-06 | 张锦铭 | 治病用灭活卡介苗 |
Non-Patent Citations (4)
Title |
---|
任月伟.丝裂霉素联合卡介苗激活的淋巴细胞对膀胱肿瘤细胞株TBC-1杀伤作用的实验研究.《华北煤炭医学院学报》.2007,第9卷(第5期),612-613. * |
晏子厚,等.治疗用卡介苗抗肿瘤动物实验方法的建立.《中国生物制品学杂志》.2002,第15卷(第6期),363-365. * |
杨丽华,等.乙型肝炎疫苗-卡介苗联合疫苗动物安全性试验研究.《微生物学免疫学进展》.2007,第35卷(第1期),19-21. * |
金立杰,等.乙型肝炎卡介苗联合疫苗与单价乙型肝炎疫苗免疫效果的比较.《中国免疫学杂志》.2006,第22卷952-955. * |
Also Published As
Publication number | Publication date |
---|---|
CN101513526A (zh) | 2009-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chang et al. | Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy | |
CN104159602B (zh) | 加强疫苗的含佐剂制剂 | |
CN1284883A (zh) | 增强核酸接种的免疫应答的方法 | |
US11185587B2 (en) | Pharmaceutical composition containing a mixture of proenzymes and enzymes | |
Hirschberg et al. | Bioneedles as alternative delivery system for hepatitis B vaccine | |
BR112015013513B1 (pt) | Composição de conjugado de proteína polissacarídica pneumocócica multivalente | |
CN101513526B (zh) | 联合疫苗在肿瘤治疗中的应用 | |
Nguyen et al. | Skin immunization with third-generation hepatitis B surface antigen using microneedles | |
CN105050617A (zh) | 免疫原性裂解物的制备方法、获得的裂解物、负载有该裂解物的树突状细胞以及含有该裂解物或树突状细胞的药物组合物 | |
WO2003049751A1 (en) | The process of manufacturing a pharmaceutical composition useful for management of cancer | |
CN110124021A (zh) | 一种新型肿瘤疫苗的制备方法 | |
KR20150065878A (ko) | 조합 백신에서 사용하기 위한 가교되지 않은 무세포 백일해 항원 | |
UA79952C2 (en) | MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT | |
US20100040625A1 (en) | Pharmaceutical Compositions Containing Monoclonal Anti-Idiotypic Anti-Ca-125 Antibody and Aluminium Derivatives | |
CN103610699A (zh) | 一种蛞蝓的提取方法及其抗肺癌应用 | |
CN104043119A (zh) | 一种新型疫苗佐剂及其制备方法 | |
US20130183340A1 (en) | Intradermal influenza vaccine | |
Yu et al. | Combination of microneedles and mf59 adjuvant as a simple approach to enhance transcutaneous immunization | |
CN114366810A (zh) | 一种可高效诱导体液和细胞免疫的天然微生物和植物来源复合双佐剂及其制备方法和应用 | |
CN106109424A (zh) | 一种猪圆环病毒2型脂质体稀释液冻干制品及其制备方法 | |
CN101704870B (zh) | 戊二酰胆固醇及其脂质体和该脂质体作为疫苗佐剂的应用 | |
CN101675994B (zh) | 治疗性疫苗制剂 | |
RU2781070C1 (ru) | Живая аттенуированная культуральная вакцина для профилактики натуральной оспы и других ортопоксвирусных инфекций на основе вируса осповакцины и способы ее получения и применения | |
CN101816631A (zh) | 用于肿瘤治疗性疫苗的脂质体制剂及其制备方法 | |
CN103505476A (zh) | 多种免疫增强剂的无细胞制剂、其制备方法及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190505 Address after: Room 702, 12 Huiyue Third Street, Haizhu District, Guangzhou City, Guangdong Province Patentee after: Vito anthracene (Guangzhou) Biomedical Technology Co.,Ltd. Address before: Room 711, Room 31, Pearl River Hospital Dormitory, Haizhu District, Guangzhou City, Guangdong 510000 Co-patentee before: Sun Libin Patentee before: Zhang Jiren |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 510000 room 702, 1 Pazhou Avenue East, Haizhu District, Guangzhou City, Guangdong Province (office only) Patentee after: Vitan (Guangzhou) Pharmaceutical Co.,Ltd. Address before: Room 702, 12 Huiyue Third Street, Haizhu District, Guangzhou City, Guangdong Province Patentee before: Vito anthracene (Guangzhou) Biomedical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201229 Address after: 570105 room 17D, 16th floor, international trade center, No.5 Yusha Road, Longhua District, Haikou City, Hainan Province Patentee after: LIFE VALLEY (HAINAN) BIOTECHNOLOGY Co.,Ltd. Address before: 510000 room 702, 1 Pazhou Avenue East, Haizhu District, Guangzhou City, Guangdong Province (office only) Patentee before: Vitan (Guangzhou) Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220830 Address after: 510000 room 702, 1 Pazhou Avenue East, Haizhu District, Guangzhou City, Guangdong Province (office only) Patentee after: Vitan (Guangzhou) Pharmaceutical Co.,Ltd. Address before: 570105 room 17D, 16th floor, international trade center, No.5 Yusha Road, Longhua District, Haikou City, Hainan Province Patentee before: LIFE VALLEY (HAINAN) BIOTECHNOLOGY Co.,Ltd. |